5028-14-8

Upstream product

• 26930-71-2 3-nitro-2-(piperidin-1-yl)pyridine 
• 1480-87-1 2-fluoro-3-nitropyridine 
• 110-89-4 piperidine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 39856-57-0 2,6-dibromo-3-aminopyridine 
• 220499-46-7 6'-bromo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-ylamine 
• 6298-19-7 2-chloro-3-aminopyridine 

Downstream Products

• 187654-70-2 Ethyl 4-(2-methylphenylamino)-8-(1-piperidino)-1,7-naphthyridin-3-carboxylate 

Relevant academic research and scientific papers

TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g, X11, X22, R11, R22, R33, R44, R55, R66, R77, R88, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non- receptor 1 (TNK1)-mediated diseases, disorders and conditions.

Pyridines IRAK4 inhibitors, preparation method and application thereof (by machine translation)

The invention belongs to the field of medicine, in particular to a formula (I) of the structural features of pyridine of compound or its pharmaceutically acceptable salt, preparation method thereof, and their use as IRAK4 inhibitors. Experimental results show that, the compound of the invention IRAK4 has prominent inhibit function, can be used for the treatment of autoimmune disease, inflammatory disease, cancer, autoimmune disease and thromboembolism as heterogeneous. (by machine translation)